Zanubrutinib Approval Status
FDA Approved: No
Generic name: zanubrutinib
Company: BeiGene, Ltd.
Treatment for: Mantle Cell Lymphoma
Zanubrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor in development for the treatment of patients with mantle cell lymphoma (MCL).
Development Status and FDA Approval Process for zanubrutinib
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.